Abstract: A breakaway medical connector can include a housing with engagement features that interface with corresponding engagement features on a breakaway member so that the breakaway is attached to the housing. A second connector can couple to the breakaway member to provide a fluid connection between the first connector and the second connector. If a force above a threshold is applied that pulls the second connector apart from the breakaway connector, the engagement features can be overcome and the breakaway member can detach from the housing. The second connector can detach from the first connector along with the breakaway member. The connector can have a valve that closes the fluid pathway upon the separation of the breakaway member from the housing. The connector can impede reconnection after the breakaway disconnection. The connector can permit reconnection using a tool that disinfects the connector.

Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

Abstract: The systems and methods are directed to leveraging the channel geometry and configuration to overcome diffusion limitations of current transduction systems. The methods may include a method of transducing target cells using a device. The device may include at least one continuous channel. The method may include delivering target cells and viral vectors into a transduction region of the channel. After transducing for some incubation time, a flushing solution may be delivered. The method may include collecting transduced cells after the transducing incubation time and the delivering of the flushing solution.

Abstract: This disclosure describes a Descemet's membrane endothelial keratoplasty (DMEK) graft prepared using paired incisions; compositions including the incised DMEK graft; an injector including the incised DMEK graft; a viewing chamber including the incised DMEK graft, methods of preparing the incised DMEK graft; and methods of using the DMEK graft, the compositions, the injectors, and the viewing chambers including to facilitate placement of DMEK grafts during cornea transplant surgery.

Abstract: The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for processing inputs using antisymmetric neural networks.

Abstract: Solid-state lighting devices, and more particularly, wire grid polarization structure for current spreading and polarization control for light emitting diode (LED) package, and a method for making the same are disclosed. The wire grid polarization structure can be configured to both polarize light emitted by an LED chip of the LED package as well as spread current on a layer of the LED chip, resulting in more even light emission across the LED chip. The wire grid polarization structure can be formed on a top surface of the LED chip, and be electrically coupled to an electrode to spread the current across the top surface of the LED chip. In an embodiment, the wire grid polarization structure can include interdigitated fingers that are coupled to both an anode and an electrode.

Abstract: A process of making an adsorbent body, wherein the process includes the steps of: (a) contacting adsorbent material with an initial mixture to form a solvated adsorbent mixture in a first solvent; (b) removing the first solvent and removing at least some of the first solvent from the solvated adsorbent mixture in the first solvent to form an initial adsorbent body; (c) contacting the initial adsorbent body with a second solvent to form a reduced-binder adsorbent body in a second solvent; and (d) solvent-drying the reduced-binder adsorbent body to form the adsorbent body. Also described is an adsorbent body, and the use of the adsorbent body in gas storage.

Abstract: Systems and methods are disclosed herein for generating and modifying a workflow comprising a series of webpages based on an online document. A document management system accesses an online document selected by a user and classifies each field of the online document into one of a set of categories. For each category, the system generates a form webpage comprising questions corresponding to each field classified as the category and combines the generated webpages to create a workflow. The system may modify the workflow by generating and adding one or more additional form webpages based on one or more answers provided by an entity completing the webform page. In response to the entity completing the modified generated workflow, the system generates a completed document based on the online document and the answers provided by the entity.

Abstract: The present invention pertains to the field of imparting or increasing resistance against fungal pathogens, in particular soy-beanrust, in plants, plant parts, and/or plant cells. This is achieved by increasing the content of scopoletin, scopolin and/or, most preferably, scoparone (6,7-di-methoxycoumarin) in a plant, plant part and/or plant cell. This can in particular be achieved by establishing and/or increasing the expression of an OMT3 enzyme and an F6H1 protein in the respective plant, plant part and/or plant cell; a further way would be to apply a formulation or solution containing scopoletin and/or, most preferably, scoparone to the plant, plant part and/or plant cell. The invention correspondingly also provides proteins, enzymes, expression constructs, plants, plant parts and/or plant cells. In this respect the invention also provides variants of the OMT3 enzyme.

Abstract: The present disclosure provides methods, compounds and compositions that are relevant to DNA-repair and DNA-repair proteins such as tyrosyl-DNA phosphodiesterase 1 (TDP1) and type I topoisomerase (TOP1).

Abstract: The present invention relates to genes and materials for improving plant health, preferably against phytopathogenic microorganisms, and/or against coumarin-induced adverse effects on plant health. Furthermore, the invention pertains to methods and uses of such genes and mate-rials for creating correspondingly beneficial plant cells, plant parts and whole plants, and also relates to products obtained from such plants or plant parts.

Abstract: The present invention is directed to a modified clostridial neurotoxin comprising a botulinum neurotoxin A (BoNT/A) Hcc domain, wherein the Hcc domain comprises a modification of methionine 1144 (MI 144), and wherein the modification increases oxidative resistance of the modified clostridial neurotoxin when compared to an otherwise identical clostridial neurotoxin lacking the modification. Also provided are (inter alia) corresponding methods for producing the same, methods for selecting oxidation resistant clostridial neurotoxins, nucleic acids encoding the same, and therapeutic uses of said modified clostridial neurotoxins.

Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesotheiin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesotheiin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesotheiin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesotheiin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesothelin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesothelin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesothelin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesothelin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: A system includes a gas turbine system including a compressor, a combustor, a turbine, and an exhaust section. The system also includes multiple sensors coupled to components of the gas turbine system. The system further includes a controller communicatively coupled to the gas turbine system and the multiple sensors and configured to control operations of the gas turbine system, wherein the controller is configured to calculate a surrogate value for turbine exit Mach number based on the feedback from the multiple sensors and to utilize the surrogate value to derive a control action for the gas turbine system.

Abstract: Systems, methods, and apparatuses are described for determining compliance with a plurality of restrictions associated with one or more devices in an organization. First text indicating restrictions may be received, and second text indicating a current configuration of one or more devices may be received. Both sets of text may be processed by, e.g., removing a portion of the text based on a predetermined list of terms and simplifying the text using a lemmatization algorithm. A first vector and second vector may be generated based on the processed sets of text, and each vector may be weighted based on an inverse frequency of words in their respective text. Each vector may be normalized based on semantic analysis. The two vectors may be compared. Based on the comparison, third text corresponding to a portion of the second vector may be generated and transmitted to a third computing device.

Abstract: A machine for comminuting laminated glass members, such as automotive windshields and architectural glass, comprises infeed rollers feeding the member over a breaker bar, where an impactor assembly breaks the glass into small fragments and the plastic disposed between layers of the glass member into larger fragments, so that a size-based separation may be employed. The speed of the infeed rollers is controlled responsive to the thickness of the glass member.